Brief

Ningbo Yun Sheng has submitted an application to the Hong Kong Stock Exchange for an H-share issuance and listing. Separately, Innovent Biologics has entered into an exclusive licensing agreement with Dimerix Limited to develop and commercialize DMX-200 in Greater China, South Korea, and parts of Southeast Asia. DMX-200 is a small molecule inhibitor targeting CCR2 and is currently in Phase 3 clinical trials for focal segmental glomerulosclerosis, having received Orphan Drug designation from the FDA and EMA. AI

The FDA has successfully implemented a real-time clinical trial data system, allowing for immediate review of patient safety signals. This transformation was driven by the rapid, agency-wide adoption of an AI assistant named Elsa, which significantly reduced task completion times for FDA staff. This initiative, alongside new AI governance principles, signals a shift towards continuous, data-native operations within the life sciences regulatory landscape, prompting urgency for the pharmaceutical industry to accelerate its own AI integration. AI

Researchers have developed two distinct deep learning frameworks for brain tumor analysis using MRI scans. One framework utilizes a Vision Transformer (ViT-B/16) for automated four-class tumor classification, achieving 99.29% accuracy and providing interpretable heatmaps of critical regions. The second approach, UniME, addresses brain tumor segmentation with missing MRI modalities by employing a two-stage heterogeneous architecture that first establishes a unified representation and then incorporates modality-specific encoders for precise segmentation. AI